{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:56:20Z","timestamp":1793242580026,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>This work aimed to optimize a celecoxib (CXB)-loaded solid lipid nanoparticles (SLN) colon delivery system for the enhancement of anticancer activity. An ultrasonic melt-emulsification method was employed in this work for the preparation of SLN. The physical attributes were characterized for their particle sizes, charges, morphology, and entrapment efficiency (%EE), in addition to DSC and FTIR. The in vitro drug release profiles were evaluated, and the anticancer activity was examined utilizing an MTT assay in three cancer cell lines: the colon cancer HT29, medulloblastoma Daoy, and hepatocellular carcinoma HepG2 cells. All of the prepared SLN formulations had nanoscale particle sizes ranging from 238 nm to 757 nm. High zeta-potential values (mv) within \u221230 s mv were reported. The %EE was in the range 86.76\u201396.6%. The amorphous nature of the SLN-entrapped CXB was confirmed from SLN DSC thermograms. The in vitro release profile revealed a slow constant rate of release with no burst release, which is unusual for SLN. Both the F9 and F14 demonstrated almost complete CXB release within 24 h, with only 25% completed within the first 5 h. F9 caused a significant percentage of cell death in the three cancer cell lines tested after 24 h of incubation and maintained this effect for 72 h. The prepared CXB-loaded SLN exhibited unique properties such as slow release with no burst and a high %EE. The anticancer activity of one formulation was extremely significant in all tested cancer cell lines at all incubation times, which is very promising.<\/jats:p>","DOI":"10.3390\/pharmaceutics14010131","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T20:21:56Z","timestamp":1641759716000},"page":"131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity"],"prefix":"10.3390","volume":"14","author":[{"given":"Hamdan N.","family":"Alajami","sequence":"first","affiliation":[{"name":"Pharmaceutical Services Administration, King Saud Medical City, Ministry of Health, Riyadh 12746, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab A.","family":"Fouad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-8045","authenticated-orcid":false,"given":"Abdelkader E.","family":"Ashour","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan 25200, Pahang Darul Makmur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[{"name":"Vitiligo Research Chair, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-7583","authenticated-orcid":false,"given":"Alaa Eldeen B.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh 11481, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"ref_1","first-page":"638","article-title":"Pharmacokinetics of Celecoxib after oral administration in dogs and humans: Effet of food and site of absorption","volume":"297","author":"Paulson","year":"2001","journal-title":"J. Pharmacol Exp. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2744(199908)25:4<231::AID-MC1>3.0.CO;2-F","article-title":"Chemotherapy activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis","volume":"25","author":"Fischer","year":"1999","journal-title":"Mol. Carcinogen."},{"key":"ref_3","first-page":"2101","article-title":"Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor","volume":"60","author":"Harris","year":"2000","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in famililal adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI119280","article-title":"Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide","volume":"99","author":"Amin","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3892\/or.2014.3334","article-title":"Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo","volume":"32","author":"Qian","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21754","DOI":"10.18632\/oncotarget.15567","article-title":"The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: Role of EGFR-RAS-FOXM1-\u03b2-catenin signaling axis","volume":"8","author":"Valverde","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/rheumatology\/39.suppl_2.21","article-title":"Celecoxib clinical profile","volume":"39","author":"Tive","year":"2000","journal-title":"Rhemuatology"},{"key":"ref_9","first-page":"263","article-title":"Topical delivery of celecoxib using microemulsion","volume":"52","author":"Subramanian","year":"2004","journal-title":"Acta Pol. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcis.2006.01.060","article-title":"Improved solubilization of Celecoxib in U-type nonionic microemulsions and their strauctural transitions with progressive aqueous dilution","volume":"299","author":"Garti","year":"2006","journal-title":"J. Colloid Interface Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/09637480701497360","article-title":"Influence of polymers on the bioavailability of microencapsulated celecoxib","volume":"24","author":"Homar","year":"2007","journal-title":"J. Microencapsule"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/acsnano.5b04137","article-title":"Celecoxib Nanoparticles for Therapeutic Angiogenesis","volume":"9","author":"Margulis","year":"2015","journal-title":"ACS Nano"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1016\/j.xphs.2016.09.019","article-title":"Stability and Ocular Pharmacokinetics of Celecoxib-Loaded Nanoparticles Topical Ophthalmic Formulations","volume":"105","author":"Ibrahim","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2015.08.093","article-title":"Mechanism of generation of drug nanocrystals in celecoxib: Mannitol nanocrystalline solid dispersion","volume":"495","author":"Bhatt","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.colsurfb.2016.10.029","article-title":"Co-delivery of multiple drug resistance inhibitors by polymer\/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance","volume":"149","author":"Wu","year":"2017","journal-title":"Colloidal Surf. B Biointerfaces"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1535-7163.MCT-16-0285","article-title":"Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma","volume":"16","author":"Gowada","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Crivelli, B., Bari, E., Perteghella, S., Catenacci, L., Mocchi, M., Farago, S., Tripodo, G., Prina-Mello, A., and Torre, M.L. (2019). Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis. Eur. J. Pharm. Biopharm., 137.","DOI":"10.1016\/j.ejpb.2019.02.008"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jps.23828","article-title":"pH-sensitive nanoparticles of curcumin-celecoxib combination: Evaluating drug synergy in ulcerative colitis model","volume":"137","author":"Gugulothu","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.2147\/IJN.S19497","article-title":"Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells","volume":"6","author":"Kim","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1021\/acsami.8b00875","article-title":"Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy","volume":"10","author":"Shi","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, B., Jin, K., Jiang, T., Want, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., and Pang, Z. (2017). Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-09520-7"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/10837450.2014.920360","article-title":"Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy","volume":"20","author":"Emami","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"ref_23","first-page":"905","article-title":"Anticancer-loaded solid lipid nanoparticles: High potential advancement in chemotherapy","volume":"8","author":"Yassin","year":"2013","journal-title":"Dig. J. Nanomater. Biostructures"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.actbio.2020.12.024","article-title":"Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique","volume":"121","author":"Arduino","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles Production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(01)00882-1","article-title":"Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages","volume":"231","author":"Hahn","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-5173(01)00660-3","article-title":"Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages","volume":"221","author":"Olbrich","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_28","first-page":"381","article-title":"Optimization of a nanostructured lipid carriers\u2019 system for enhancing biopharmaceutical properties of valsartan","volume":"12","author":"Albekery","year":"2017","journal-title":"Dig. J. Nanomater. Biostructures"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11095-006-0022-2","article-title":"Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules","volume":"23","author":"Peltier","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1166\/jnn.2006.423","article-title":"Interacellular Accumulation and Cytotoxicity of Doxorubicin with Different Pharmaceutical Formulations in Human Cancer Cell Lines","volume":"6","author":"Serpe","year":"2006","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-5173(97)00222-6","article-title":"Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN)","volume":"157","author":"Schwarz","year":"1997","journal-title":"Int. J. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jpba.2004.02.005","article-title":"Determiniation of celecoxib in human plasma by high-performance liquid chromatography","volume":"35","author":"Jalalizadeh","year":"2004","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7150\/ijms.7.398","article-title":"Optimization of 5-fluorouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer","volume":"7","author":"Yassin","year":"2010","journal-title":"Int. J. Med. Sci."},{"key":"ref_34","first-page":"2393","article-title":"Formulation and Evaluation of Lidocaine Lipid Nanosystems for Dermal Delivery","volume":"10","author":"Pathak","year":"2009","journal-title":"AAPS PharmaSciTech"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","article-title":"Application of Akaike\u2019s Information Criterion (AIC) in the Evaluation of Linear Pharmacokinetic Equations","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0022-1759(93)90012-V","article-title":"A new approach for measurement of cytotoxicity using colorimetric assay","volume":"160","author":"Hussain","year":"1993","journal-title":"J. Immunol. Methods"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.biopha.2018.07.102","article-title":"Novel docetaxel chitosan-coated PLGA\/PCL nanoparticles with magnified cytotoxicity and bioavailability","volume":"106","author":"Badran","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.toxlet.2012.10.008","article-title":"Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway","volume":"215","author":"Elumalai","year":"2012","journal-title":"Toxicol. Lett."},{"key":"ref_39","unstructured":"Mulhen, A.Z. (1996). Feste Lipid-Nanopartikl mit prolongierter Wirkstoffiberation: Herstellung, Langzeitstabilitat, Charakterisierung, Freisetzungsverhalten und-Mechanismen. [Ph.D. Thesis, Freie Universitat]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2009.08.035","article-title":"Self-nanoemulsifying drug delivery system for oral delivery of Zedoary essential oil: Formulation and bioavailability studies","volume":"383","author":"Zhao","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s11095-007-9234-3","article-title":"Effect of solid lipid nanoparticles formulation compositions on particle size and zeta potential and potential for in-vitro pHIS-HIV-hugag transfection","volume":"6","author":"Asasutjarit","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/pt0804083","article-title":"Investigations of the effect of the lipid matrix on drug entrapment, in vitro release and physical stability of Olanzapine-Loaded Solid Lipid Nanoparticles","volume":"83","author":"Vivek","year":"2007","journal-title":"AAPS PharmaSciTech"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1208\/s12248-014-9674-8","article-title":"Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: A systematic study based on a quality by design approach","volume":"17","author":"Patil","year":"2015","journal-title":"AAPS J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i1.10","article-title":"Physical chemical considerations of lipid-based oral drug delivery- solid lipid nanoparticles","volume":"21","author":"Bummer","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijpharm.2006.05.017","article-title":"Extruded and spheronized beads containing Carbopol\u00ae 974P to deliver nonelectrolytes and salts of weakly basic drugs","volume":"321","author":"Bommareddy","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0301-4622(94)00136-8","article-title":"Stability of emulsions stabilised by two physiological surfactants: L-alpha-phosphatidylcholine and sodium taurocholate","volume":"54","author":"Foster","year":"1995","journal-title":"Biophys. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013A review of the state of the art","volume":"50","author":"Gohla","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1208\/s12249-009-9197-2","article-title":"Diazepam-loaded Solid Lipid Nanoparticle: Design and Characterization","volume":"10","author":"Abdelbary","year":"2009","journal-title":"AAPS PharmaSciTech"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1186\/1476-511X-8-6","article-title":"Lipid nanoparticles for transdermal for transdermal delivery of flurbiprofen: Formulation, in vitro, ex vivo and in vivo studies","volume":"8","author":"Bhaskar","year":"2009","journal-title":"Lipids Health Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijpharm.2004.07.017","article-title":"Investigations on the flow behavior of dispersions of solid triglycerides nanoparticles","volume":"284","author":"Illing","year":"2004","journal-title":"Int. J. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1021\/jp9912612","article-title":"Observation of size dependent melting in lipid nanoparticles","volume":"47","author":"Unruh","year":"1999","journal-title":"J. Phys. Chem. B."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s003960000436","article-title":"Investigations on the melting behavior of triglyceride nanoparticles","volume":"279","author":"Unruh","year":"2001","journal-title":"Colloid Polym. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/3-540-47822-1_2","article-title":"Effects of surfactants on the crystallization and polymorphism of lipid nanoparticles","volume":"121","author":"Bunjes","year":"2002","journal-title":"Prog. Colloid Polym. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1021\/la990856l","article-title":"Effect of Particle Size on Colloidal Solid Triglycerides","volume":"12","author":"Bunjes","year":"2000","journal-title":"Langmuir"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijpharm.2005.04.014","article-title":"Thermal analysis of the crystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin","volume":"298","author":"Schubert","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0939-6411(97)00150-1","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013Drug release and release mechanism","volume":"45","author":"Schwarz","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_57","first-page":"329","article-title":"Study by X-ray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles","volume":"41","author":"Cavalli","year":"1995","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_58","first-page":"392","article-title":"The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules","volume":"53","author":"Cavalli","year":"1998","journal-title":"Pharmazie"},{"key":"ref_59","unstructured":"CRC Press (2012). Structural elucidation of organic compounds. Linearly Polarized IR Spectroscop, Theory and Applications for Structural Analysis, Taylor & Francis Group, LLC."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/1061186X.2010.504264","article-title":"A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma","volume":"19","author":"Barakat","year":"2011","journal-title":"J. Drug Target."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/02652040500444198","article-title":"DEET-loaded solid lipid particles for skin delivery: In vitro release and skin permeation characteristics in different vehicles","volume":"23","author":"Iscan","year":"2006","journal-title":"J. Microencapsul."},{"key":"ref_62","first-page":"552","article-title":"Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles","volume":"53","author":"Muhlen","year":"1998","journal-title":"Pharmazie"},{"key":"ref_63","first-page":"766","article-title":"Sterilization and physical stability of drug- free and etomidate loaded solid lipid nanoparticles","volume":"22","author":"Shwartz","year":"1995","journal-title":"Proc. Int. Symp. Cont. Rel. Bioact. Mater."},{"key":"ref_64","first-page":"129","article-title":"Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability","volume":"9","author":"Ibrahim","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4314\/tjpr.v19i5.1","article-title":"Enhancement of ciprofloxacin activity by incorporating it in solid lipid nanoparticles","volume":"19","author":"Alarifi","year":"2020","journal-title":"Trop. J. Pharm. Res."},{"key":"ref_66","unstructured":"Kiss, E.L., Berk\u00f3, S., G\u00e1csi, A., Kov\u00e1cs, A., Katona, G., So\u00f3s, J., Cs\u00e1nyi, E., Gr\u00f3f, I., Harazin, A., and Deli, M.A. (2019). Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use. Pharmaceutics, 14."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/157341212803341663","article-title":"Risperidone Release from Solid Lipid Nanoparticles (SLN): Validated HPLC Method and Modelling Kinetic Profile","volume":"8","author":"Silva","year":"2012","journal-title":"Curr. Pharm. Anal."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1574885514666190103114200","article-title":"Development & Pharmaceutical Characterization of Isoniazid Loaded Solid Lipid Nanoparticle Drug Delivery Approach","volume":"14","author":"Kushwaha","year":"2019","journal-title":"Curr. Drug Ther."},{"key":"ref_69","first-page":"217","article-title":"Formulation and evaluation of NSAID-Loaded Tristearin Solid Lipid Nanoparticles","volume":"4","author":"Kishore","year":"2011","journal-title":"Int. J. Med. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3892\/ol.2014.2439","article-title":"Hedgehog-glioma-associated oncogene homolog-1 signaling in colon cancer cells and its role in the celecoxib-mediated anti-cancer effect","volume":"8","author":"Wang","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijpharm.2015.01.016","article-title":"Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells","volume":"479","author":"Limasale","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/jps.23674","article-title":"In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines","volume":"102","author":"Limasale","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.3748\/wjg.v11.i40.6281","article-title":"Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis","volume":"11","author":"Liu","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-14-51","article-title":"The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX\/COX inhibitors: An analysis of gene expression","volume":"14","author":"Chlapek","year":"2014","journal-title":"Cancer Cell Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"111103","DOI":"10.1016\/j.biopha.2020.111103","article-title":"Nanomedicines: Redefining traditional medicine","volume":"134","author":"Lu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_76","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: Lipid-based nanoformulations","volume":"8","author":"Mudassir","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nano.2008.08.003","article-title":"Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery","volume":"5","author":"Paliwal","year":"2009","journal-title":"Nanomedicine"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/1\/131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:12:55Z","timestamp":1760364775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/1\/131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["pharmaceutics14010131"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14010131","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}